FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025532007> ?p ?o ?g. }

• W2025532007 endingPage "S45" @default.
• W2025532007 startingPage "S41" @default.
• W2025532007 abstract "To alleviate the risk of variceal bleeding, the portal pressure gradient — usually evaluated as the hepatic venous pressure gradient (HVPG) — must be reduced to ≤ 12 mmHg. Although β-blocking agents are accepted therapy for preventing first or subsequent bleeding episodes, propranolol therapy decreases final HVPG to ≤ 12 mmHg in only 12% of patients, while only 24% of patients have a ≥ 20% reduction in HVPG and nearly 40% show no reduction in HVPG. This has stimulated research on alternative or additional treatments. Nitrates such as isosorbide dinitrate reduce portal pressure by decreasing resistance to portal and collateral blood flow and by promoting reflex splanchnic vasoconstriction. However, while nitrates are effective in the acute situation, tolerance leading to refractoriness develops over the long term unless they are combined with diuretics or other agents in the treatment of portal hypertension. Propranolol and isosorbide-5-mononitrate combined cause a substantially greater reduction in HVPG than monotherapy with either drug in both acute and long-term use. Presumably concomitant isosorbide-5-mononitrate administration opposes the increase in portal resistance induced by propranolol. Spironolactone, which has been shown to lower HVPG in patients with cirrhosis, produces a reduction in plasma volume that attenuates the increased cardiac output associated with cirrhosis and triggers vasoactive mechanisms that decrease splanchnic blood flow. Potentially, spironolactone may maintain and enhance the decrease in portal pressure achieved by nitrates or propranolol. Triple therapy with a β-blocker, a nitrate and spironolactone may be feasible. Serotonin constricts mesenteric veins in experimental models of portal hypertension and may also play a role in portal hypertension secondary to cirrhosis. Serotonin S2-receptor blockers, such as ritanserin and ketanserin, have been shown to lower portal-collateral resistance in animal models and patients with cirrhosis. These serotonin antagonists should be assessed for their potential in coadministration with non-selective β-blockers, perhaps with the addition of spironolactone. To alleviate the risk of variceal bleeding, the portal pressure gradient — usually evaluated as the hepatic venous pressure gradient (HVPG) — must be reduced to ≤ 12 mmHg. Although β-blocking agents are accepted therapy for preventing first or subsequent bleeding episodes, propranolol therapy decreases final HVPG to ≤ 12 mmHg in only 12% of patients, while only 24% of patients have a ≥ 20% reduction in HVPG and nearly 40% show no reduction in HVPG. This has stimulated research on alternative or additional treatments. Nitrates such as isosorbide dinitrate reduce portal pressure by decreasing resistance to portal and collateral blood flow and by promoting reflex splanchnic vasoconstriction. However, while nitrates are effective in the acute situation, tolerance leading to refractoriness develops over the long term unless they are combined with diuretics or other agents in the treatment of portal hypertension. Propranolol and isosorbide-5-mononitrate combined cause a substantially greater reduction in HVPG than monotherapy with either drug in both acute and long-term use. Presumably concomitant isosorbide-5-mononitrate administration opposes the increase in portal resistance induced by propranolol. Spironolactone, which has been shown to lower HVPG in patients with cirrhosis, produces a reduction in plasma volume that attenuates the increased cardiac output associated with cirrhosis and triggers vasoactive mechanisms that decrease splanchnic blood flow. Potentially, spironolactone may maintain and enhance the decrease in portal pressure achieved by nitrates or propranolol. Triple therapy with a β-blocker, a nitrate and spironolactone may be feasible. Serotonin constricts mesenteric veins in experimental models of portal hypertension and may also play a role in portal hypertension secondary to cirrhosis. Serotonin S2-receptor blockers, such as ritanserin and ketanserin, have been shown to lower portal-collateral resistance in animal models and patients with cirrhosis. These serotonin antagonists should be assessed for their potential in coadministration with non-selective β-blockers, perhaps with the addition of spironolactone." @default.
• W2025532007 created "2016-06-24" @default.
• W2025532007 creator A5001524643 @default.
• W2025532007 creator A5012387403 @default.
• W2025532007 creator A5025880516 @default.
• W2025532007 creator A5027268186 @default.
• W2025532007 creator A5029332100 @default.
• W2025532007 creator A5061511331 @default.
• W2025532007 creator A5087615789 @default.
• W2025532007 date "1993-01-01" @default.
• W2025532007 modified "2023-10-17" @default.
• W2025532007 title "New approaches in the pharmacologic treatment of portal hypertension" @default.
• W2025532007 cites W122518412 @default.
• W2025532007 cites W1490907837 @default.
• W2025532007 cites W1535966969 @default.
• W2025532007 cites W1554641506 @default.
• W2025532007 cites W1654654375 @default.
• W2025532007 cites W1963712775 @default.
• W2025532007 cites W197303752 @default.
• W2025532007 cites W1990693343 @default.
• W2025532007 cites W1991110995 @default.
• W2025532007 cites W1994397083 @default.
• W2025532007 cites W1997131223 @default.
• W2025532007 cites W1998640491 @default.
• W2025532007 cites W2001650220 @default.
• W2025532007 cites W2007677328 @default.
• W2025532007 cites W2018946904 @default.
• W2025532007 cites W2025606754 @default.
• W2025532007 cites W2046652300 @default.
• W2025532007 cites W2060806941 @default.
• W2025532007 cites W2071142226 @default.
• W2025532007 cites W2073998389 @default.
• W2025532007 cites W2086373569 @default.
• W2025532007 cites W2091806278 @default.
• W2025532007 cites W2108579436 @default.
• W2025532007 cites W2119658569 @default.
• W2025532007 cites W2132069560 @default.
• W2025532007 cites W2136558062 @default.
• W2025532007 cites W2141076725 @default.
• W2025532007 cites W2144567094 @default.
• W2025532007 cites W2144807882 @default.
• W2025532007 cites W2167366369 @default.
• W2025532007 cites W2181133001 @default.
• W2025532007 cites W2328498131 @default.
• W2025532007 cites W2417180058 @default.
• W2025532007 cites W2419219009 @default.
• W2025532007 cites W25352667 @default.
• W2025532007 cites W51546379 @default.
• W2025532007 doi "https://doi.org/10.1016/s0168-8278(05)80455-6" @default.
• W2025532007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8098342" @default.
• W2025532007 hasPublicationYear "1993" @default.
• W2025532007 type Work @default.
• W2025532007 sameAs 2025532007 @default.
• W2025532007 citedByCount "27" @default.
• W2025532007 crossrefType "journal-article" @default.
• W2025532007 hasAuthorship W2025532007A5001524643 @default.
• W2025532007 hasAuthorship W2025532007A5012387403 @default.
• W2025532007 hasAuthorship W2025532007A5025880516 @default.
• W2025532007 hasAuthorship W2025532007A5027268186 @default.
• W2025532007 hasAuthorship W2025532007A5029332100 @default.
• W2025532007 hasAuthorship W2025532007A5061511331 @default.
• W2025532007 hasAuthorship W2025532007A5087615789 @default.
• W2025532007 hasConcept C126322002 @default.
• W2025532007 hasConcept C158846371 @default.
• W2025532007 hasConcept C164705383 @default.
• W2025532007 hasConcept C2775849017 @default.
• W2025532007 hasConcept C2776379505 @default.
• W2025532007 hasConcept C2777214474 @default.
• W2025532007 hasConcept C2778151854 @default.
• W2025532007 hasConcept C2778198053 @default.
• W2025532007 hasConcept C2778808290 @default.
• W2025532007 hasConcept C2778949068 @default.
• W2025532007 hasConcept C2781033279 @default.
• W2025532007 hasConcept C42219234 @default.
• W2025532007 hasConcept C56900294 @default.
• W2025532007 hasConcept C58245268 @default.
• W2025532007 hasConcept C71924100 @default.
• W2025532007 hasConcept C84393581 @default.
• W2025532007 hasConceptScore W2025532007C126322002 @default.
• W2025532007 hasConceptScore W2025532007C158846371 @default.
• W2025532007 hasConceptScore W2025532007C164705383 @default.
• W2025532007 hasConceptScore W2025532007C2775849017 @default.
• W2025532007 hasConceptScore W2025532007C2776379505 @default.
• W2025532007 hasConceptScore W2025532007C2777214474 @default.
• W2025532007 hasConceptScore W2025532007C2778151854 @default.
• W2025532007 hasConceptScore W2025532007C2778198053 @default.
• W2025532007 hasConceptScore W2025532007C2778808290 @default.
• W2025532007 hasConceptScore W2025532007C2778949068 @default.
• W2025532007 hasConceptScore W2025532007C2781033279 @default.
• W2025532007 hasConceptScore W2025532007C42219234 @default.
• W2025532007 hasConceptScore W2025532007C56900294 @default.
• W2025532007 hasConceptScore W2025532007C58245268 @default.
• W2025532007 hasConceptScore W2025532007C71924100 @default.
• W2025532007 hasConceptScore W2025532007C84393581 @default.
• W2025532007 hasLocation W20255320071 @default.
• W2025532007 hasLocation W20255320072 @default.
• W2025532007 hasOpenAccess W2025532007 @default.
• W2025532007 hasPrimaryLocation W20255320071 @default.

• next